A Prognostic Signature for Lung Adenocarcinoma by Five Genes Associated with Chemotherapy in Lung Adenocarcinoma

Overview

Journal Clin Respir J

Specialty Pulmonary Medicine

Date 2023 Dec 10

PMID 38071755

Authors

Xiaofeng Li

Chunwei Xu

Yonghua Min

Zhanqiang Zhai

Youcai Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Lung adenocarcinoma (LUAD) is one of the most common subtypes of lung cancer. Finding prognostic biomarkers is helpful in stratifying LUAD patients with different prognosis.

Methods: We explored the correlation of LUAD prognosis and genes associated with chemotherapy in LUAD and obtained data of LUAD patients from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Drug sensitivity data were acquired from the Genomics of Drug Sensitivity in Cancer (GDSC) database. Differential and enrichment analyses were used to screen the target genes utilizing limma and "clusterProfiler" packages. Then univariate and LASSO Cox analyses were used to select the prognosis-related genes. Survival analysis was used to estimate the overall survival (OS) of different groups.

Results: Twenty-three differentially expressed genes (DEGs) were screened between LUAD samples and healthy samples, and BTK, FGFR2, PIM2, CHEK1, and CDK1 were selected to construct a prognostic signature. The OS of patients in the high-risk group (risk score higher than 0.69) was worse than that in the low-risk group (risk score lower than 0.69).

Conclusion: The risk score model constructed by five genes is a potential prognostic biomarker for LUAD patients.

Citing Articles

Identification of potential core genes in lung cancer and therapeutic traditional Chinese medicine compounds using bioinformatics analysis.

Zhang Y, Wang Y, Zhang X, Liu J Medicine (Baltimore). 2024; 103(39):e39862.

PMID: 39331864 PMC: 11441908. DOI: 10.1097/MD.0000000000039862.

A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma.

Li X, Xu C, Min Y, Zhai Z, Zhu Y Clin Respir J. 2023; 17(12):1349-1360.

PMID: 38071755 PMC: 10730453. DOI: 10.1111/crj.13723.

References

Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H . CDK1 in Breast Cancer: Implications for Theranostic Potential. Anticancer Agents Med Chem. 2020; 20(7):758-767. DOI: 10.2174/1871520620666200203125712. View

Li L, Zhang S, Wei L, Wang Z, Ma W, Liu F . FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer. Oncol Lett. 2018; 16(2):2490-2494. PMC: 6036565. DOI: 10.3892/ol.2018.8903. View

Kuhn E, Morbini P, Cancellieri A, Damiani S, Cavazza A, Comin C . Adenocarcinoma classification: patterns and prognosis. Pathologica. 2018; 110(1):5-11. View

Liang J, Li H, Han J, Jiang J, Wang J, Li Y . Mex3a interacts with LAMA2 to promote lung adenocarcinoma metastasis via PI3K/AKT pathway. Cell Death Dis. 2020; 11(8):614. PMC: 7427100. DOI: 10.1038/s41419-020-02858-3. View

Wang B, Huang J, Chen H, Lin C, Lin S, Hung W . The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol. 2019; 146(1):43-52. DOI: 10.1007/s00432-019-03079-8. View

Long J, Wang A, Bai Y, Lin J, Yang X, Wang D . Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019; 42:363-374. PMC: 6491941. DOI: 10.1016/j.ebiom.2019.03.022. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Wang F, Gu T, Chen Y, Chen Y, Xiong D, Zhu Y . Long non-coding RNA SOX21-AS1 modulates lung cancer progress upon microRNA miR-24-3p/PIM2 axis. Bioengineered. 2021; 12(1):6724-6737. PMC: 8806559. DOI: 10.1080/21655979.2021.1955578. View

Fadaka A, Bakare O, Sibuyi N, Klein A . Gene Expression Alterations and Molecular Analysis of CHEK1 in Solid Tumors. Cancers (Basel). 2020; 12(3). PMC: 7139733. DOI: 10.3390/cancers12030662. View

10.

Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini P . Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget. 2018; 8(67):111836-111846. PMC: 5762363. DOI: 10.18632/oncotarget.22912. View

11.

Sun J, Zhao T, Zhao D, Qi X, Bao X, Shi R . Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients. Ther Adv Med Oncol. 2020; 12:1758835920937904. PMC: 7333486. DOI: 10.1177/1758835920937904. View

12.

Stilgenbauer S, Furman R, Zent C . Management of chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2015; :164-75. DOI: 10.14694/EdBook_AM.2015.35.164. View

13.

Costa-Pinheiro P, Montezuma D, Henrique R, Jeronimo C . Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015; 7(6):1003-15. DOI: 10.2217/epi.15.56. View

14.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

15.

Hook J, Penberthy J, Davis D, Van Tongeren D . Inquiry-based stress reduction: A systematic review of the empirical literature. J Clin Psychol. 2021; 77(6):1280-1295. DOI: 10.1002/jclp.23120. View

16.

Wu P, Zheng Y, Wang Y, Wang Y, Liang N . Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma. J Transl Med. 2020; 18(1):380. PMC: 7542703. DOI: 10.1186/s12967-020-02545-z. View

17.

Gong Y, Pang H, Yu Z, Wang X, Li P, Zhang Q . Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity. Ann Med. 2023; 55(1):2200034. PMC: 10124980. DOI: 10.1080/07853890.2023.2200034. View

18.

Minashi K, Yamada T, Hosaka H, Amagai K, Shimizu Y, Kiyozaki H . Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer. Jpn J Clin Oncol. 2021; 51(10):1523-1533. PMC: 8491535. DOI: 10.1093/jjco/hyab104. View

19.

Yue C, Ma H, Zhou Y . Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma. PeerJ. 2019; 7:e8128. PMC: 6886493. DOI: 10.7717/peerj.8128. View

20.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View